For the fifth year in a row, Endocrine News spoke with editors from Endocrine Society journals to get the scoop on the top endocrine discoveries of 2019. Here is part 2 of Eureka! 2019. Endocrinology associate editor Patricia Brubaker, PhD, FRSC, professor, Departments of Physiology and Medicine at the University of Toronto, in Ontario, credits “Gestational Diabetes Adversely Affects Pancreatic...
In his session at ENDO 2019, Jeffrey Boord, MD, MPH, proposed the use of clinical pharmacists in primary care practices to help manage patients as well as overcome clinical inertia. Clinical inertia is one of the issues that can be a deterrence to optimal care for diabetes patients in a primary care setting, which, according...
Researchers have identified a protein kinase that controls weight and homeostasis and when deficient or inactivated can lead to metabolic diseases like obesity and type 2 diabetes, according to a mouse study recently published in Endocrinology. Researchers led by Eiichi Hinoi of the Laboratory of Pharmacology in the Department of Bioactive Molecules at Gifu Pharmaceutical...
Robert Gabbay, MD, PhD, kicked off the “Diabetes Innovative Models of Care: Taking Back Your Practice with Innovation” sessions at ENDO 2019 by instructing attendees how simply reconnecting with their original passion could possibly extinguish burnout. Incorporating new forms of innovation could be the answer. ENDO 2019, as always, provided attendees with numerous changes to...
As more and more patients with diabetes embrace continuous glucose monitor technology, an international consensus group points to ways clinicians and patients can apply continuous glucose monitor data to minimize glucose highs and lows. With more diabetes patients adopting continuous glucose monitors (CGM), endocrinologists are wrestling with questions about how best to use all that...
Daniel J. Drucker, MD, is having a very good year. In September, he received the 2019 EASD–Novo Nordisk Foundation Diabetes Prize for Excellence due to his outstanding scientific contributions that have increased our knowledge of diabetes and the biology of gut hormones. In October, he was honored with the 2019 Harold Hamm International Prize for Biomedical...
The Institute of Diabetes and Regeneration Research at Helmholtz Zentrum München and Eli Lilly and Company (Lilly) have partnered with the goal of improving and accelerating the treatment of diabetes mellitus. Diabetes mellitus’s long-term complications and co-morbidities represent one of the most devastating and urgent threats to society. While significant progress has been made in...
The U.S. Food and Drug Administration (FDA) recently approved a ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. Xeris Pharmaceuticals is marketing this new glucagon injection as GVOKE. GVOKE is the first glucagon product approved that can be administered via...
In his session at ENDO 2019, Jeffrey Boord, MD, MPH, proposed the use of clinical pharmacists in primary care practices to help manage patients as well as overcome clinical inertia. Clinical inertia is one of the issues that can be a deterrence to optimal care for diabetes patients in a primary care setting, which, according...
Robert Gabbay, MD, PhD, kicked off the “Diabetes Innovative Models of Care: Taking Back Your Practice with Innovation” sessions at ENDO 2019 by instructing attendees how simply reconnecting with their original passion could possibly extinguish burnout. Incorporating new forms of innovation could be the answer. ENDO 2019, as always, provided attendees with numerous changes to...
Daniel J. Drucker, MD, is having a very good year. In September, he received the 2019 EASD–Novo Nordisk Foundation Diabetes Prize for Excellence due to his outstanding scientific contributions that have increased our knowledge of diabetes and the biology of gut hormones. In October, he was honored with the 2019 Harold Hamm International Prize for Biomedical...
